Ascelia Pharma – Update on re-evaluation of Sparkle headline data


Meet and ask questions to CEO Magnus Corfitzen from Ascelia Pharma on 20 september 2023 at 10 AM.Ascelia Pharma has now completed the plan for the required re-evaluation of SPARKLE images. In the new plan, headline results from SPARKLE are expected by May 2024.Read full announcement here: Pharma is a biotech company focused on orphan oncology treatments. The company develops and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. The company has two drug candidates – Orviglance® (Mangoral) and Oncoral – in clinical development. Ascelia Pharma has its global headquarters in Malmö, Sweden, and is listed on Nasdaq Stockholm (ticker: ACE)Disclaimer: HC Andersen Capital receives payment from Ascelia Pharma for a DigitalIR/Corporate Visibility agreement./Claus Thestrup 14-09-2023 3.23PM.